ESMO 2022 on the ELAINE Trial: Lasofoxifene vs. Fulvestrant for Locally Advanced or Metastatic ER+/HER2- BC | VuMedi

ecancer

ESMO 2022 on the ELAINE Trial: Lasofoxifene vs. Fulvestrant for Locally Advanced or Metastatic ER+/HER2- BC

By ecancer FEATURING Matthew Goetz

By ecancer FEATURING Matthew Goetz

174 views

September 28, 2022

0 Comments

Login to view comments. Click here to Login